

Resource Summary Report

Generated by [nidm-terms](#) on Jul 28, 2026

FlowJo

RRID:SCR_008520

Type: Tool

Proper Citation

FlowJo (RRID:SCR_008520)

Resource Information

URL: <https://www.flowjo.com/solutions/flowjo>

Proper Citation: FlowJo (RRID:SCR_008520)

Description: Software for single-cell flow cytometry analysis. Its functions include management, display, manipulation, analysis and publication of the data stream produced by flow and mass cytometers.

Synonyms: FlowJo®

Resource Type: software application, software resource, data processing software, data analysis software

Keywords: single-cell analysis, flow cytometry, flow cytometer, mass cytometer

Resource Name: FlowJo

Resource ID: SCR_008520

Alternate IDs: nif-0000-30575

Record Creation Time: 20220129T080247+0000

Record Last Update: 20260728T043306+0000

Ratings and Alerts

No rating or validation information has been found for FlowJo.

No alerts have been found for FlowJo.

Data and Source Information

Usage and Citation Metrics

We found 67274 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Avanessian SC, et al. (2026) IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy. *Cancer immunology research*, 14(1), 122.

Herbrich S, et al. (2026) TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors. *Cancer cell*, 44(1), 187.

Lieb WS, et al. (2026) Protein kinase D deficiency induces a senescence-like phenotype in β -cells and improves glucose and insulin tolerance under high-fat diet conditions. *Molecular metabolism*, 103, 102297.

Ghaemi B, et al. (2026) Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma. *Theranostics*, 16(6), 2748.

Kim H, et al. (2026) Myelin antigen capture in the CNS by B cells expressing EBV latent membrane protein 1 leads to demyelinating lesion formation. *Cell*.

Liang Y, et al. (2026) SLC39A10 drives M2 macrophage polarization and gastric cancer progression through the MAPK14(p38 γ) pathway. *iScience*, 29(1), 114400.

Mogi M, et al. (2026) Pan-cancer analysis of RNA expression signatures associated with cancer tissue architecture. *British journal of cancer*, 134(1), 141.

Lahme K, et al. (2026) Autoantibody-triggered podocyte membrane budding drives autoimmune kidney disease. *Cell*, 189(1), 123.

Stern YE, et al. (2026) Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. *Cancer research*, 86(2), 485.

Hamagami N, et al. (2026) State-specific enhancer landscapes govern microglial plasticity. *Immunity*.

Stolarik E, et al. (2026) Inhibition of cell surface GRP78 on brain tumors reverses drug resistance and stops cancer stem cell expansion. *The Journal of biological chemistry*, 111146.

Fernandes P, et al. (2026) Functional immune responses induced by a capsid assembly modulator in chronic hepatitis B virus-infected humanized mice. *Cell host & microbe*, 34(1), 116.

Mao S, et al. (2026) Loss of cyclin C drives resistance to anti-TIGIT therapy by upregulating CD155-mediated immune evasion. *Drug resistance updates : reviews and*

commentaries in antimicrobial and anticancer chemotherapy, 84, 101318.

Eme-Scolan E, et al. (2026) Remodeling of skull bone channels regulates immune infiltration into the meninges during neuroinflammation. *Immunity*, 59(1), 116.

Monteiro AC, et al. (2026) OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer. *Cancer research communications*, 6(1), 85.

Miranda K, et al. (2026) Loss of $\alpha 7$ nicotinic acetylcholine receptor exacerbates adrenergic-induced cardiac damage. *American journal of physiology. Cell physiology*.

Maerz MD, et al. (2026) BCG vaccination induces antibacterial effector functions among V $\alpha 1/3$ T cells that are associated with protection against tuberculosis. *Cell reports. Medicine*, 102536.

Lee J, et al. (2026) Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer. *Science advances*, 12(1), eady0041.

Huang X, et al. (2026) Integrin/CD44-targeted liposomes remodel the pulmonary microenvironment to alleviate acute exacerbation of pulmonary fibrosis. *Journal of controlled release : official journal of the Controlled Release Society*, 389, 114427.

Saini P, et al. (2026) Targeting Interactions Between Siglec-10 and $\alpha 3\beta 1$ Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. *Cancer research*, 86(1), 99.